Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin-13 (IL-13) signaling via the IL-4 receptor alpha (IL-4Rα) primarily occurs through the type II receptor complex, composed of IL-4Rα and IL-13Rα1. IL-13 binds to IL-13Rα1, which then recruits IL-4Rα to form the functional receptor. This complex activates downstream signaling pathways, notably the JAK/STAT6 pathway, leading to gene expression changes associated with Th2 responses, alternative macrophage activation, and the promotion of allergic inflammation, airway hyperresponsiveness, and fibrosis. IL-13Rα2 acts as a decoy receptor, attenuating IL-13 signaling.
Blocking IL-13 binding to the IL-4R alpha/IL-13R alpha1 receptor complex, inhibiting downstream signaling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin 13 signaling via IL-4 receptor alpha.